TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05409352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure
Description: Participants will receive training of self-acupressure on the 5 standard acupoints by a trained traditional Chinese medicine (TCM) practitioner, have return-demonstration, be assessed by the practitioner with the use of a competency checklist, and be instructed to perform self-acupressure on the standard acupoints once a day. A follow-up visit will be conducted to reinforce learning, in which participants will demonstrate the acupressure technique while the practitioner observes and provides feedback, including suggestions for technique adjustments if necessary. The practitioner will recommend 2 additional acupoints from the list of optional acupoints based on the patients' sensitivity to acupoint stimulation and preference. Daily duration of self-practice will range from 8-10 minutes depending on the semi-individualized protocol (5 standard + 2 optional acupoints).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Participants will receive verbal and written information from a trained exercise specialist about the specific advice of the desired exercise frequency (3x/week), duration (30 min each time), and intensity (moderate determined by rating of 12 to 14 on the Borg Rating of Perceived Exertion scale). The exercise specialist will demonstrate how to perform walking at moderate intensity indoors and outdoors, followed by return-demonstration of the patient. Education on safety precautions and walk schedule planning will be provided. Competency check will be performed to assess participants' ability to self-monitor and self-regular exercise intensity using Borg Scale. One week after the start of the program, the exercise specialist will conduct a 1-hour follow-up visit to supervise the patient's walking session and assess whether there is any additional advice needed.
Study: NCT04888949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell
Description: 1\*10\^8 cells are administered once a week, total four times intravenously.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available saline.
Study: NCT05551117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: 2.7 mg.kg IV every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: 2.7 mg.kg IV every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: 2.7 mg.kg IV every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: 2.7 mg.kg IV every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: 1000 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: 160 mg daily
Study: NCT04695366

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05824091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7762 (TBD09)
Description: Cohort 1: 50 mg Cohort 2: 150 mg Cohort 3: 300 mg Cohort 4: 600 mg Cohort 5: TBD Cohort 6: TBD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A subset of participants from each of the 6 dosing cohorts will receive placebo.
Study: NCT05602350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administered survey
Description: Subjects will self-administer questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enumerator-administered survey
Description: Subjects will have enumerator-administered questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
Study: NCT04676698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three Good Things
Description: The treatment phase will last 3 weeks. However, participants will complete surveys at baseline and up to 6 months. At the end of the trial the study team will also select a limited number of entries from participants to share some of the good things which people listed. These will be edited to ensure writer anonymity and participants will be informed of this plan in the study introduction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait list control arm and then Three Good Things
Description: Surveys will be completed for 3 months prior to treatment and then after treatment.
Study: NCT06287190

Intervention type: OTHER
Intervention: Dental interns
Description: Assessing self-assessment
Study: NCT04956926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS201
Description: JS201 is administered intravenously Q3W at the corresponding dose.
Study: NCT06137560

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single vision spectacle lens
Description: Standard single vision spectacle lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single vision spectacle lens + S.T.O.P.® Kit 1
Description: Standard single vision spectacle lens + S.T.O.P.® Kit 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single vision spectacle lens + S.T.O.P.® Kit 2
Description: Standard single vision spectacle lens + S.T.O.P.® Kit 2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single vision spectacle lens + S.T.O.P.® Film
Description: Standard single vision spectacle lens + S.T.O.P.® Film

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2
Description: Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2
Study: NCT05960942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol combined with esketamine
Description: In group PE, esketamine was firstly administered at a dose of 0.3 mg.kg-1, followed immediately by propofol with a single intravenous dose of 2.0 mg.kg-1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol-sufentanil
Description: In group PS, sufentanil was administered intravenously at a dose of 0.2 μg.kg-1, then 2.0 mg.kg-1 propofol was intravenously injected.
Study: NCT05017285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HoLEP with median lobe preservation
Description: Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum

Intervention type: PROCEDURE
Group type: OTHER
Intervention: HoLEP classic
Description: Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).
Study: NCT04409795

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin Extended Release Oral Tablet
Description: Initial oral hypoglycemic agent added to existing insulin treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin Extended Release Oral Tablet
Description: Initial oral hypoglycemic agent added to existing insulin treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: Secondary oral hypoglycemic agent added to existing insulin treatment (for those who are intolerant to or unable to achieve glycemic targets with metformin)

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: Secondary oral hypoglycemic agent added to existing insulin treatment (for those who are intolerant to or unable to achieve glycemic targets with metformin)
Study: NCT06472258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Artesunate
Description: IV artesunate with a weight-appropriate dosage at 0, 12, 24, and 48 hours and continued 12-hourly for a maximum duration of seven days, with each dose diluted in normal saline and given as an infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Artesunate
Description: IV artesunate with a weight-appropriate dosage at 0, 12, 24, and 48 hours and continued 12-hourly for a maximum duration of seven days, with each dose diluted in normal saline and given as an infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Quinine Hydrochloride
Description: IV Quinine hydrochloride in accordance to weight with loading dose 20mg salt/kg in 10% dextrose infusion followed by 10mg salt/kg infusion 8 hourly for 2 days and for 12 hourly onwards for a maximum of 7 days.
Study: NCT06555692

Intervention type: BIOLOGICAL
Intervention: Transplant acellular dermal matrix(ADM)
Description: The principle of surgery is the pectoral muscle preservation (prepectoral) method and the subpectoral method (Breast Reconstruction using implants). After wrapping the implant with acellular dermal matrix(ADM), it is inserted into the breast and fixed to the underlying muscle or surrounding tissue depending on the situation.

Intervention type: BIOLOGICAL
Intervention: Transplant acellular dermal matrix(ADM)
Description: The principle of surgery is the pectoral muscle preservation (prepectoral) method and the subpectoral method (Breast Reconstruction using implants). After wrapping the implant with acellular dermal matrix(ADM), it is inserted into the breast and fixed to the underlying muscle or surrounding tissue depending on the situation.
Study: NCT05523401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-bromo-2,5-dimethoxyphenethylamine (10 mg)
Description: A low dose of 10 mg 2C-B will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-bromo-2,5-dimethoxyphenethylamine (20 mg)
Description: A medium dose of 20 mg 2C-B will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-bromo-2,5-dimethoxyphenethylamine (30 mg)
Description: A high dose of 30 mg 2C-B will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3,4-methylenedioxymethamphetamine
Description: A moderate dose of 125 mg MDMA will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: A moderate dose of 25 mg psilocybin will be administered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Mannitol)
Study: NCT05300867

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurorehabilitation
Description: Neurorehabilitation with soft exsoskeleton robotic 3-week-long

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy 3-week-long
Study: NCT06083077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest wall strapping
Description: An elastic band (6 cm wide) is placed around the lower part of the chest wall (at the junction of the chest and abdomen) to tighten the chest wall for 10 min at PEEP 7 cmH2O and 10 min without PEEP
Study: NCT06557915

Intervention type: PROCEDURE
Intervention: screening
Description: screening and detection of nasal problems in Neonates and Infants Subjected to CPAP
Study: NCT04925908

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR for SARS-Cov-2
Description: Nasopharyngeal swab for detecting Novel Coronavirus-2 by reverse transcriptase polymerase chain reaction

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR for SARS-Cov-2
Description: Nasopharyngeal swab for detecting Novel Coronavirus-2 by reverse transcriptase polymerase chain reaction
Study: NCT05466929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeACH System Resources
Description: Patients who screen positive for anxiety will receive psychoeducation and mental health recommendations (e.g., evidence-based apps) selected for use with the TeACH System through a collaborative, stakeholder-engaged approach completed in phases 1 and 2 of this project.
Study: NCT06496464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Phase 1 MASTER Coach Development Workshop (weeks 1) PE teachers participated in a 6-hour theory and practical teacher education workshop to a research team (JY) member, including 4h of reading relevant papers and books regarding the game-based approach (GBA) .~Phase 2 Eight weeks of teaching mentoring (weeks 2-7) This 8-week phase involved coaches implementing MASTER elements (e.g. 10-minute stretching before a sports game, teachers will give 1-2 sentences of praise during the game for individual students who make a reasonable effort) in their regular training sessions.~Phase 3 3 weeks peer assessed teaching/discussions (weeks 8-10) The mentor prepared and implement a 2-h training session designed to highlight important aspects of the MASTER framework and games-based coaching practices.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intervention
Description: Phase 1 MASTER Coach Development Workshop (weeks 1) PE teachers participated in a 6-hour theory and practical teacher education workshop to a research team (JY) member, including 4h of reading relevant papers and books regarding the game-based approach (GBA) .~Phase 2 Eight weeks of teaching mentoring (weeks 2-7) This 8-week phase involved coaches implementing MASTER elements (e.g. 10-minute stretching before a sports game, teachers will give 1-2 sentences of praise during the game for individual students who make a reasonable effort) in their regular training sessions.~Phase 3 3 weeks peer assessed teaching/discussions (weeks 8-10) The mentor prepared and implement a 2-h training session designed to highlight important aspects of the MASTER framework and games-based coaching practices.
Study: NCT05207839

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk powder
Description: one sachet per day dissolved in 200 ml of water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk powder
Description: one sachet per day dissolved in 200 ml of water
Study: NCT06637189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix
Description: Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitively binding to GnRH receptors in the pituitary gland. Consequently, there is a reversible, intense, and rapid suppression of endogenous gonadotropin release. Ganirelix is indicated for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive techniques (ART).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone Acetate 10 MG
Description: Medroxyprogesterone acetate is a synthetic progestin (structurally related to progesterone) with antiestrogenic, antiandrogenic, and antigonadotropic action. It inhibits pituitary gonadotropins (FSH and LH) with consequent inhibition of follicular maturation and ovulation . Medroxyprogesterone acetate is active orally and parenterally, 15 times more potent than progesterone. In addition to inhibiting ovulation, progestins also act on the endometrium preventing implantation and increasing the viscosity of cervical mucus, which hinders sperm progression in the uterus. It also transforms a proliferative endometrium into a secretory endometrium, provided that the woman has adequate endogenous estrogen levels.
Study: NCT05966714

Intervention type: DEVICE
Intervention: NIRS
Description: cerebral oxygenation and electrical activity monitoring

Intervention type: DEVICE
Intervention: NIRS
Description: cerebral oxygenation and electrical activity monitoring

Intervention type: DEVICE
Intervention: NIRS
Description: cerebral oxygenation and electrical activity monitoring

Intervention type: DEVICE
Intervention: NIRS
Description: cerebral oxygenation and electrical activity monitoring

Intervention type: DEVICE
Intervention: aEEG
Description: amplitude-integrated electroencephalography

Intervention type: DEVICE
Intervention: aEEG
Description: amplitude-integrated electroencephalography

Intervention type: DEVICE
Intervention: aEEG
Description: amplitude-integrated electroencephalography

Intervention type: DEVICE
Intervention: aEEG
Description: amplitude-integrated electroencephalography
Study: NCT06639802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Arm Bimanual Intensive therapy including lower extremity (HABIT-ILE)
Description: HABIT-ILE is continuous intervention applied for 50-90 hours over two weeks. We will design the activities based on the findings of the initial assessments (T0) and the customized functional goals that were previously discussed with the parents (e.g., drinking on one\&#39;s own without spilling, using one hand to hold a book while turning pages with the other, removing a t-shirt, etc.). HABIT-ILE activities are presented as games and the whole environment is arranged in such a way that children perceive the therapy as fun. Progression of difficulty depend upon success in performance of current level. Specific bi-manual activities are selected on basis of child's motor abilities, age and interest.
Study: NCT06638190

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 100% Orange juice
Description: 250 mL of commercial 100% orange juice containing 25 g of total sugars (glucose, fructose, saccharose).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50% Orange juice
Description: 250 mL of 50% diluted orange juice (100% orange juice) plus added sugars to attain the same concentration and composition of sugars (glucose, fructose, saccharose) as the 100% orange juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0% Orange juice
Description: 250 mL of water plus added sugars to attain the same concentration and composition of sugars (glucose, fructose, saccharose) as the 100% orange juice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 250 mL of water with 25 g of glucose. To determine the glycemic index of the different drinks and to characterize the glucose and insuline response of the participants

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 100% Orange juice Rep
Description: Repetition of the 100% orange juice intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0% Orange juice Rep
Description: Repetition of the 0% orange juice intervention
Study: NCT05052736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Neuromodulation
Description: The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 20 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-invasive Neuromodulation
Description: The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 20 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
Study: NCT06641492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chatbot-delivered interventions tailored to one's stage of changes
Description: The Chatbot will assess participants' physical activity level and stage of changes regarding physical activity and automatically deliver interventions tailor to their stage of changes every week for 12 weeks. The Chatbot will address questions related to physical activity raised by the participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chatbot-delivered standard interventions
Description: The Chatbot will not assess participants' stage of changes. It will assess participants' physical activity level and provides a standard intervention covering general information about physical activity for older adults, which is not tailoring to participants' stage of changes every week for 12 weeks. The Chatbot will address questions related to physical activity raised by the participants.
Study: NCT06439810

Intervention type: DIAGNOSTIC_TEST
Intervention: Mycobacterium tuberculosis (MTB) cell-free DNA (cfDNA)
Description: Comparing the diagnostic accuracy between MTB cfDNA and PCR on diagnosing tuberculous pleuritis

Intervention type: DIAGNOSTIC_TEST
Intervention: Mycobacterium tuberculosis (MTB) cell-free DNA (cfDNA)
Description: Comparing the diagnostic accuracy between MTB cfDNA and PCR on diagnosing tuberculous pleuritis
Study: NCT06561776

Intervention type: OTHER
Intervention: Physical Evaluations of individuals
Description: Participants will be evaluated on cough strength, physical activity and balance. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
Study: NCT06642129

Intervention type: PROCEDURE
Intervention: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
Description: Lumboperitoneal shunt (LPS) involves connecting the subarachnoid space of the lumbar spine to the peritoneal cavity through a pressure-adjustable unidirectional valve to shunt the appropriate amount of cerebrospinal fluid from the ventricles to the peritoneal cavity via the spinal canal, where it is absorbed through the peritoneum, to alleviate the increased intracranial pressure caused by the communicating hydrocephalus and the corresponding clinical symptoms.
Study: NCT06640231

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sealer activation after cleaning and shaping with XP-Endo Finisher
Description: activation of sealer before the obturation of root canals

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: negative control where canals are obturated directly without sealer activation
Description: sealer after cleaning and shaping before the obturation without using activation method
Study: NCT06637774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspirometer
Description: a triaxial accelerometer and a contact microphone affixed with tape to patient neck, a data accrual infrastructure, algorithms that decode swallow physiology noninvasively

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videofluoroscopic X-ray
Description: MBS is a fluoroscopic diagnostic test to evaluate swallowing physiology. Its images are judged by humans trained to do so.
Study: NCT06639048

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire including demographic characteristics, social media usage habits, body weight, height, effects of social media on eating behavior scale and eating disorder fear questionnaire.
Study: NCT05812690

Intervention type: OTHER
Intervention: This is a non intervention - observation only study
Description: This is non intervention study

Intervention type: OTHER
Intervention: This is a non intervention - observation only study
Description: This is non intervention study
Study: NCT06640647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1005 injection or placebo
Description: HDM1005 injection or placebo isubcutaneous injection once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1005 injection or placebo
Description: HDM1005 injection or placebo isubcutaneous injection once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1005 injection or placebo
Description: HDM1005 injection or placebo isubcutaneous injection once